JP2008507253A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507253A5
JP2008507253A5 JP2006551695A JP2006551695A JP2008507253A5 JP 2008507253 A5 JP2008507253 A5 JP 2008507253A5 JP 2006551695 A JP2006551695 A JP 2006551695A JP 2006551695 A JP2006551695 A JP 2006551695A JP 2008507253 A5 JP2008507253 A5 JP 2008507253A5
Authority
JP
Japan
Prior art keywords
humanized antibody
antibody
seq
composition
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006551695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/000142 external-priority patent/WO2005075647A1/en
Publication of JP2008507253A publication Critical patent/JP2008507253A/ja
Publication of JP2008507253A5 publication Critical patent/JP2008507253A5/ja
Pending legal-status Critical Current

Links

JP2006551695A 2004-02-06 2005-02-04 ヒト化抗体 Pending JP2008507253A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54194404P 2004-02-06 2004-02-06
PCT/CA2005/000142 WO2005075647A1 (en) 2004-02-06 2005-02-04 Humanized antibody

Publications (2)

Publication Number Publication Date
JP2008507253A JP2008507253A (ja) 2008-03-13
JP2008507253A5 true JP2008507253A5 (enExample) 2008-04-24

Family

ID=34837529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551695A Pending JP2008507253A (ja) 2004-02-06 2005-02-04 ヒト化抗体

Country Status (9)

Country Link
US (2) US20050226883A1 (enExample)
EP (1) EP1718749A4 (enExample)
JP (1) JP2008507253A (enExample)
CN (1) CN1965082A (enExample)
AU (1) AU2005210695A1 (enExample)
BR (1) BRPI0509495A2 (enExample)
CA (1) CA2555306A1 (enExample)
EA (1) EA010687B1 (enExample)
WO (1) WO2005075647A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
AU2007240614B2 (en) * 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
WO2009137677A2 (en) * 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
EP3279215B1 (en) * 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
CN115724951B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 与11型hpv结合的抗体或其抗原结合片段及其应用
WO2024226646A2 (en) * 2023-04-25 2024-10-31 Memorial Sloan-Kettering Cancer Center Dlk1 -targeting antibodies and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA1340110C (en) * 1987-12-09 1998-11-03 Jack R. Wands Carcinoma-associated antigens, and antibodies which recognize these antigens
EP0353450B1 (en) * 1988-06-24 1995-03-29 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0526888A3 (en) * 1991-08-06 1993-09-01 Toray Industries, Inc. Monoclonal antibody reactive with human pancreas cancer tissue
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69334156T2 (de) * 1992-11-16 2008-04-10 Centocor, Inc. Verfahren zur Reduzierung der Immunogenizität der variablen Regionen von Antikörpern
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0745612B1 (en) * 1995-05-26 2001-11-07 MERCK PATENT GmbH Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
AU3276197A (en) * 1996-06-27 1998-01-14 Yamanouchi Pharmaceutical Co., Ltd. Drugs for ameliorating renal disorders
AU4373197A (en) * 1996-09-19 1998-04-14 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6450642B1 (en) * 1999-01-12 2002-09-17 California Institute Of Technology Lenses capable of post-fabrication power modification
JP2000206146A (ja) * 1999-01-19 2000-07-28 Mitsubishi Electric Corp プロ―ブ針
DE19957543C1 (de) * 1999-11-30 2001-07-19 Infineon Technologies Ag Dreitransistor-DRAM-Zelle und dazugehöriges Herstellungsverfahren
BR0209990A (pt) * 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
US20030009756A1 (en) * 2001-07-05 2003-01-09 Pace Micro Technology Plc. Internet browser as part fo a broadcast data receiver
DE60217507T2 (de) * 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Similar Documents

Publication Publication Date Title
CN112135626B (zh) 抗tigit抗体及其用途
Goel et al. Relative position of the hexahistidine tag effects binding properties of a tumor-associated single-chain Fv construct
CN108367075B (zh) 4-1bb结合蛋白及其用途
EP3183272B1 (en) Asymmetric multispecific antibodies
CN117510635A (zh) C-kit结合剂
DK2644205T3 (en) Targeting ABCB5 for Cancer Therapy
US9701756B2 (en) Humanized antibody or fragment thereof specific for CD45R0
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN104271602A (zh) 双特异性抗体
AU2017241161A1 (en) Binding proteins and methods of use thereof
JPH05502384A (ja) 抗体の調製
CA2753541A1 (en) Antibodies to troponin i and methods of use thereof
KR20130010123A (ko) ＴＮＦ-α 결합 단백질
CN114981301B (zh) Pd1和vegfr2双结合剂
CA2454361A1 (en) Humanized antibodies
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
AU2026202717A1 (en) Anti c-met antibodies
JP2019506140A5 (enExample)
KR20240107202A (ko) 항-트랜스페린 수용체 항체 및 이의 용도
US20210347882A1 (en) Antibodies to human resistin
CN115397857B (zh) 一种抗pd-l1和pd-l2抗体及其衍生物和用途
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
WO2003062370B1 (en) Multimeric proteins and methods of making and using same
CN118696058A (zh) 抗bcma纳米抗体及其应用
CN114106195A (zh) 一种多功能融合蛋白及其用途